| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03256649 |
| P698 | PubMed publication ID | 14720002 |
| P2093 | author name string | Peter D O Davies | |
| P2860 | cites work | Directly observed therapy for tuberculosis: history of an idea | Q40484237 |
| Directly observed therapy. Who is responsible? | Q41428813 | ||
| Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default | Q41682968 | ||
| Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan | Q43541487 | ||
| Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries | Q43956041 | ||
| Coping with Africa's increasing tuberculosis burden: are community supervisors an essential component of the DOT strategy? Directly observed therapy | Q46239216 | ||
| Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis | Q46492075 | ||
| New hope for the treatment of multi-drug-resistant tuberculosis? | Q47575917 | ||
| Tuberculosis: history of directly observed therapy. | Q53639875 | ||
| Directly observed therapy and treatment adherence | Q56837004 | ||
| The emergence of drug-resistant tuberculosis in New York City | Q28262856 | ||
| Trends in mortality from tuberculosis in England and Wales: effect of age on deaths from non-respiratory disease | Q33605161 | ||
| Tuberculosis in New York City--turning the tide | Q34059053 | ||
| Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa | Q36247375 | ||
| What makes DOT work? Directly observed therapy | Q39018160 | ||
| Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs | Q39251526 | ||
| Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment | Q39445241 | ||
| A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis | Q39449544 | ||
| A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States | Q39480318 | ||
| High-compliance tuberculosis treatment programme in a rural community | Q39594047 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| P304 | page(s) | 203-209 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Treatments in Respiratory Medicine | Q15755236 |
| P1476 | title | The role of DOTS in tuberculosis treatment and control | |
| P478 | volume | 2 |
| Q40829439 | A luminescence assay for natural product inhibitors of the Mycobacterium tuberculosis proteasome |
| Q24681801 | Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development |
| Q42248267 | Direct monthly highly active antiretroviral therapy supply - a method to increase patient's adherence and outcome. Experience of one AIDS centre in Israel |
| Q35841643 | Efficacy of directly observed treatment short-course intermittent regimen in spinal tuberculosis |
| Q55257820 | Evaluation of the Directly Observed Treatment's Acceptance by Tuberculosis Patients in the Republic of Macedonia. |
| Q35743972 | Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives |
| Q35960910 | In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment |
| Q58716400 | Linking cytochrome P450 enzymes from Mycobacterium tuberculosis to their cognate ferredoxin partners |
| Q47862158 | More than ten years of DOTS in Bosnia and Herzegovina |
| Q58126485 | Spinal Tuberculosis - Directly Observed Treatment and Short Course or Daily Anti Tubercular Therapy -Are We Over Treating? |
| Q38617197 | The anti-tuberculosis agents under development and the challenges ahead |
| Q47549661 | The identification of risk factors associated with patient and healthcare system delays in the treatment of tuberculosis in Tabriz, Iran |
| Q36203224 | Tuberculosis in London: a decade and a half of no decline [corrected]. |
| Q59136838 | Use of Geographically Weighted Poisson Regression to examine the effect of distance on Tuberculosis incidence: A case study in Nam Dinh, Vietnam |
| Q35692558 | Use of eCompliance, an innovative biometric system for monitoring of tuberculosis treatment in rural Uganda |
| Q44118420 | Why tuberculosis service providers do not follow treatment guideline in Ethiopia: a qualitative study |
Search more.